Push For Genetically Engineered Therapeutics Drives Cell-Culture Market

Cell-Culture Market Biotechnology and biopharmaceutical companies are putting the pressure on manufacturers of cell-culture equipment and supplies to create products that will enable researchers to culture cells more efficiently and in large amounts. The increased need for these products is an outgrowth of the growing demand for genetically engineered products with proven or potential therapeutic value. The laboratory products industry is responding with new types of cell-culture vessels that

Written byHolly Ahern
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Cell-Culture Market Biotechnology and biopharmaceutical companies are putting the pressure on manufacturers of cell-culture equipment and supplies to create products that will enable researchers to culture cells more efficiently and in large amounts. The increased need for these products is an outgrowth of the growing demand for genetically engineered products with proven or potential therapeutic value.

The laboratory products industry is responding with new types of cell-culture vessels that boast specially treated surfaces to which cultured cells may firmly adhere. Also on the market are new formulations of culture media, as well as instruments that allow researchers to grow vast quantities of cells while continuously collecting the prized protein product that the cells secrete as they grow in culture.

Several types of cells, from sources as diverse as bacteria and humans, retain their ability to synthesize and secrete the protein products characteristic of the tissue from whence they came. In ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies